✦ LIBER ✦

Production and Molecular Characterization of Clinical Phase I Anti-Melanoma Mouse IgG3 Monoclonal Antibody R24

✍ Scribed by Sven E. Kemminer; Harald S. Conradt; Manfred Nimtz; Diana Šagi; Jasna Peter-Katalinić; Oliver Diekmann; Irena Drmić; Johannes Müthing

Book ID: 109386300
Publisher: American Institute of Chemical Engineers
Year: 2001
Tongue: English
Weight: 267 KB
Volume: 17
Category: Article
ISSN: 8756-7938
DOI: 10.1021/bp010068y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of buffering conditions and cult

Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24

✍ Johannes Müthing; Sven E. Kemminer; Harald S. Conradt; Dijana Šagi; Manfred Nimt 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB 👁 1 views

A phase I study of anti-GD3 ganglioside

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma

✍ Lori M. Minasian; Tzy Jyun Yao; Thomas A. Steffens; David A. Scheinberg; Linda W 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Blocking of interleukin 2 (IL 2) binding

Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18

✍ Athanasia Mouzaki; Hans-Dieter Volk; Hisao Osawa; Tibor Diamantstein 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 727 KB

A mouse anti-rat interleukin 2 (IL 2) receptor (IL 2R) monoclonal antibody (mAb), ART-65, has been developed. As shown by fluorescence-activated cell sorter analysis and immunoprecipitation studies, ART-65 recognizes in a species-specific manner the same molecule as does ART-18, a mAb which has been